Progress the pre-clinical development of DNDI-6174 for the treatment of visceral leishmaniasis
current phase of drug development
updated 1 Jun 2021
Emerging from the leishmaniasis L205 lead optimization series after showing great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis, DNDI-6174 was nominated as a pre-clinical candidate for visceral leishmaniasis in 2019. DNDI-6174 presents a new mode of action among compounds in DNDi’s leishmaniasis portfolio as well as a predicted low human dose and a very promising safety margin.
Get our latest news, personal stories, research articles, and job opportunities.